@article{GentzschHoffmannOhshimaetal.2021,
  author    = {Gentzsch, Christian and Hoffmann, Matthias and Ohshima, Yasuhiro and Nose, Naoko and Chen, Xinyu and Higuchi, Takahiro and Decker, Michael},
  title     = {Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer},
  series = {ChemMedChem},
  volume    = {16},
  journal   = {ChemMedChem},
  number    = {9},
  doi       = {10.1002/cmdc.202000942},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239904},
  pages     = {1427 -- 1437},
  year      = {2021},
  abstract  = {The enzyme butyrylcholinesterase (BChE) represents a promising target for imaging probes to potentially enable early diagnosis of neurodegenerative diseases like Alzheimer's disease (AD) and to monitor disease progression in some forms of cancer. In this study, we present the design, facile synthesis, in vitro and preliminary ex vivo and in vivo evaluation of a morpholine-based, selective inhibitor of human BChE as a positron emission tomography (PET) tracer with a pseudo-irreversible binding mode. We demonstrate a novel protecting group strategy for 18F radiolabeling of carbamate precursors and show that the inhibitory potency as well as kinetic properties of our unlabeled reference compound were retained in comparison to the parent compound. In particular, the prolonged duration of enzyme inhibition of such a morpholinocarbamate motivated us to design a PET tracer, possibly enabling a precise mapping of BChE distribution.},
  language  = {en}
}
@article{HofmannFayezScheineretal.2020,
  author    = {Hofmann, Julian and Fayez, Shaimaa and Scheiner, Matthias and Hoffmann, Matthias and Oerter, Sabrina and Appelt-Menzel, Antje and Maher, Pamela and Maurice, Tangui and Bringmann, Gerhard and Decker, Michael},
  title     = {Sterubin: Enantioresolution and Configurational Stability, Enantiomeric Purity in Nature, and Neuroprotective Activity in Vitro and in Vivo},
  series = {Chemistry - A European Journal},
  volume    = {26},
  journal   = {Chemistry - A European Journal},
  number    = {32},
  doi       = {10.1002/chem.202001264},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-215993},
  pages     = {7299 -- 7308},
  year      = {2020},
  abstract  = {Alzheimer′s disease (AD) is a neurological disorder with still no preventive or curative treatment. Flavonoids are phytochemicals with potential therapeutic value. Previous studies described the flavanone sterubin isolated from the Californian plant Eriodictyon californicum as a potent neuroprotectant in several in vitro assays. Herein, the resolution of synthetic racemic sterubin (1) into its two enantiomers, (R)-1 and (S)-1, is described, which has been performed on a chiral chromatographic phase, and their stereochemical assignment online by HPLC-ECD coupling. (R)-1 and (S)-1 showed comparable neuroprotection in vitro with no significant differences. While the pure stereoisomers were configurationally stable in methanol, fast racemization was observed in the presence of culture medium. We also established the occurrence of extracted sterubin as its pure (S)-enantiomer. Moreover, the activity of sterubin (1) was investigated for the first time in vivo, in an AD mouse model. Sterubin (1) showed a significant positive impact on short- and long-term memory at low dosages.},
  language  = {en}
}
@article{GuneschHoffmannKiermeieretal.2020,
  author    = {Gunesch, Sandra and Hoffmann, Matthias and Kiermeier, Carolina and Fischer, Wolfgang and Pinto, Antonio F. M. and Maurice, Tangui and Maher, Pamela and Decker, Michael},
  title     = {7-O-Esters of taxifolin with pronounced and overadditive effects in neuroprotection, anti-neuroinflammation, and amelioration of short-term memory impairment in vivo},
  series = {Redox Biology},
  volume    = {29},
  journal   = {Redox Biology},
  doi       = {10.1016/j.redox.2019.101378},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-202718},
  pages     = {101378},
  year      = {2020},
  abstract  = {Alzheimer's disease (AD) is a multifactorial disease and the most common form of dementia. There are no treatments to cure, prevent or slow down the progression of the disease. Natural products hold considerable interest for the development of preventive neuroprotectants to treat neurodegenerative disorders like AD, due to their low toxicity and general beneficial effects on human health with their anti-inflammatory and antioxidant features. In this work we describe regioselective synthesis of 7-O-ester hybrids of the flavonoid taxifolin with the phenolic acids cinnamic and ferulic acid, namely 7-O-cinnamoyltaxifolin and 7-O-feruloyltaxifolin. The compounds show pronounced overadditive neuroprotective effects against oxytosis, ferroptosis and ATP depletion in the murine hippocampal neuron HT22 cell model. Furthermore, 7-O-cinnamoyltaxifolin and 7-O-feruloyltaxifolin reduced LPS-induced neuroinflammation in BV-2 microglia cells as assessed by effects on the levels of NO, IL6 and TNFα. In all in vitro assays the 7-O-esters of taxifolin and ferulic or cinnamic acid showed strong overadditive activity, significantly exceeding the effects of the individual components and the equimolar mixtures thereof, which were almost inactive in all of the assays at the tested concentrations. In vivo studies confirmed this overadditive effect. Treatment of an AD mouse model based on the injection of oligomerized Aβ\(_{25-35}\) peptide into the brain to cause neurotoxicity and subsequently memory deficits with 7-O-cinnamoyltaxifolin or 7-O-feruloyltaxifolin resulted in improved performance in an assay for short-term memory as compared to vehicle and mice treated with the respective equimolar mixtures. These results highlight the benefits of natural product hybrids as a novel compound class with potential use for drug discovery in neurodegenerative diseases due to their pharmacological profile that is distinct from the individual natural components.},
  language  = {en}
}